# OnCo record prostate (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate" ;
  schema:name "Prostate cancer"@en ;
  schema:alternateName "Prostatic acinar adenocarcinoma"@en, "Acinar adenocarcinoma of the prostate"@en, "Adenocarcinoma of the prostate"@en, "Prostate carcinoma"@en, "Carcinoma of the prostate"@en, "CaP"@en ;
  schema:description "Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."@en ;
  schema:url <https://onco.cc/cancers/prostate/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q181257> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459>, <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations>, <https://www.rcpath.org/static/8cc88604-2c8d-4df4-a99542df41c102af/G084-dataset-for-histopathology-reports-for-prostatic-carcinoma.pdf>, <https://tumourclassification.iarc.who.int/chapters/36>, <https://doi.org/10.1111/his.14711>, <https://doi.org/10.1002/ijc.70561>, <https://www.uicc.org/news-and-updates/25-7-announcements/9th-edition-uicc-tnm-classification-malignant-tumours-now-available>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/27-prostate-fact-sheet.pdf>, <https://seer.cancer.gov/statfacts/html/prost.html>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer>, <https://www.nhs.uk/conditions/prostate-cancer/symptoms/>, <https://doi.org/10.1002/bco2.60>, <https://pubmed.ncbi.nlm.nih.gov/35965208/>, <https://doi.org/10.1097/PAS.0000000000000530>, <https://www.nhs.uk/conditions/prostate-cancer/>, <https://www.nhs.uk/conditions/prostate-cancer/tests-and-next-steps/>, <https://www.nhs.uk/conditions/prostate-cancer/treatment/>, <https://www.nhs.uk/conditions/prostate-cancer/help-and-support/>, <https://www.nhs.uk/conditions/erection-problems-erectile-dysfunction/>, <https://www.nhs.uk/symptoms/priapism-painful-erections/>, <https://www.nhs.uk/conditions/urinary-incontinence/>, <https://www.nhs.uk/conditions/sepsis/>, <https://www.nhs.uk/tests-and-treatments/clinical-trials/>, <https://www.nhs.uk/social-care-and-support/support-and-benefits-for-carers/carer-assessments/>, <https://www.nhs.uk/social-care-and-support/support-and-benefits-for-carers/benefits-for-carers/>, <https://www.nice.org.uk/guidance/ng234/chapter/Recommendations>, <https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed>, <https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/localised-prostate-cancer>, <https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/dealing-with-my-diagnosis>, <https://prostatecanceruk.org/prostate-information-and-support/treatments/choosing-a-treatment>, <https://prostatecanceruk.org/prostate-information-and-support/treatments/follow-up-after-treatment>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you/hot-flushes>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/sex-and-relationships>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/sex-and-relationships/treatments-for-erection-problems>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/urinary-problems>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/pelvic-floor-muscle-exercises>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/fatigue>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/the-emotional-impact>, <https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/physical-activity-and-prostate-cancer>, <https://prostatecanceruk.org/prostate-information-and-support/advanced-prostate-cancer/metastatic-spinal-cord-compression-mscc>, <https://prostatecanceruk.org/prostate-information-and-support/get-support/our-specialist-nurses>, <https://www.macmillan.org.uk/cancer-information-and-support/prostate-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/hormonal-therapies>, <https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/hormone-therapy>, <https://theros.org.uk/>, <https://www.mariecurie.org.uk/information/getting-care/palliative-care>, <https://www.maggies.org/support-and-information/>, <https://doi.org/10.1056/NEJMoa2214122>, <https://doi.org/10.1056/NEJMoa1606221>, <https://doi.org/10.1056/EVIDoa2300018>, <https://doi.org/10.1056/NEJMoa041943>, <https://doi.org/10.1200/JCO.2006.06.2497>, <https://doi.org/10.1056/NEJMoa2004325>, <https://doi.org/10.1016/S1470-2045(09)70338-9>, <https://doi.org/10.1016/j.urolonc.2017.07.016>, <https://view-health-screening-recommendations.service.gov.uk/prostate-cancer/>, <https://www.nice.org.uk/guidance/ng131>, <https://www.natcan.org.uk/wp-content/uploads/2025/10/NPCA-SotN-2025.pdf>, <https://prostatecanceruk.org/> ;
  onco:tag "gu", "spike" ;
  onco:related <https://onco.cc/roadmaps/radiopharma-roadmap/>, <https://onco.cc/pairings/psma-pet-to-rlt/>, <https://onco.cc/pairings/beta-then-alpha/>, <https://onco.cc/pairings/parp-plus-arpi/>, <https://onco.cc/pairings/ai-pathology-to-adt/>, <https://onco.cc/collections/src-urotoday/>, <https://onco.cc/cancers/prostate-ductal-adenocarcinoma/>, <https://onco.cc/cancers/prostate-nepc/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/>, <https://onco.cc/cancers/prostate-bcr/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-nmcrpc/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/>, <https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/>, <https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/>, <https://onco.cc/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/>, <https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/>, <https://onco.cc/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/>, <https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/>, <https://onco.cc/biomarkers/ar-amplification/>, <https://onco.cc/biomarkers/ar-ligand-binding-domain-mutation/>, <https://onco.cc/biomarkers/ar-v7-splice-variant/>, <https://onco.cc/biomarkers/hrr-gene-mutation/>, <https://onco.cc/biomarkers/tmprss2-erg-fusion/>, <https://onco.cc/biomarkers/spop-mutation/>, <https://onco.cc/biomarkers/nepc-transformation/>, <https://onco.cc/biomarkers/ctdna-tumour-fraction/>, <https://onco.cc/biomarkers/psma-pet-expression/>, <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/pten-alteration/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/hrd-positive/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:technologies <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/prostate-screening-psa-mri/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/psma/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/steap1/>, <https://onco.cc/targets/klk2/>, <https://onco.cc/targets/grpr/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/cdk12/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/erg/>, <https://onco.cc/targets/tmprss2/>, <https://onco.cc/targets/foxa1/>, <https://onco.cc/targets/spop/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/etv1/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/msh2/>, <https://onco.cc/targets/nkx3-1/>, <https://onco.cc/targets/apc/>, <https://onco.cc/targets/kmt2c/>, <https://onco.cc/targets/zbtb16/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/aurka/>, <https://onco.cc/targets/cdkn1b/> ;
  onco:drugs <https://onco.cc/drugs/paige-prostate/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/nilutamide/>, <https://onco.cc/drugs/triptorelin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/padeliporfin/>, <https://onco.cc/drugs/samarium-153-lexidronam/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/drugs/estramustine/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/drugs/sipuleucel-t/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/drugs/bicalutamide/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/halda-therapeutics/>, <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/futurechem/>, <https://onco.cc/companies/hinova-pharmaceuticals/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/spectracure/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/lantheus/>, <https://onco.cc/companies/telix/>, <https://onco.cc/companies/curium/>, <https://onco.cc/companies/veracyte/>, <https://onco.cc/companies/artera/> ;
  onco:institutions <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/peter-mac/>, <https://onco.cc/institutions/ucla-jonsson/>, <https://onco.cc/institutions/uke-hamburg/>, <https://onco.cc/institutions/johns-hopkins/>, <https://onco.cc/institutions/gustave-roussy/>, <https://onco.cc/institutions/prostate-cancer-uk/>, <https://onco.cc/institutions/uclh/>, <https://onco.cc/institutions/leeds-cancer-centre/>, <https://onco.cc/institutions/the-christie/>, <https://onco.cc/institutions/clatterbridge/>, <https://onco.cc/institutions/imperial-cancer-centre/>, <https://onco.cc/institutions/velindre-cardiff/>, <https://onco.cc/institutions/beatson-glasgow/>, <https://onco.cc/institutions/northern-ireland-cancer-centre/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/prostate-cancer-signalling/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/base-excision-repair-parp/>, <https://onco.cc/pathways/synthetic-lethality-map/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/ubiquitin-proteasome-system/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/chromosomal-instability/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/intravasation-ctc-survival/> ;
  onco:terms <https://onco.cc/terms/psa/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/terms/psa50/>, <https://onco.cc/terms/ar-v7/>, <https://onco.cc/terms/theranostics/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/crossover/>, <https://onco.cc/terms/cambridge-prognostic-group/>, <https://onco.cc/terms/tnm-prostate-cancer/>, <https://onco.cc/terms/prostate-acinar-adenocarcinoma/>, <https://onco.cc/terms/intraductal-carcinoma-prostate/>, <https://onco.cc/terms/cribriform-prostate-cancer/>, <https://onco.cc/terms/percentage-gleason-pattern-4/>, <https://onco.cc/terms/psa-density/>, <https://onco.cc/terms/extraprostatic-extension/>, <https://onco.cc/terms/high-grade-pin/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/mcrpc-mhspc/>, <https://onco.cc/terms/psa-kinetics/>, <https://onco.cc/terms/active-surveillance-term/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/grade-vs-stage/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/prostatectomy/>, <https://onco.cc/terms/orchiectomy/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/overdiagnosis/>, <https://onco.cc/terms/adt/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/screening/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/hazard-ratio/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/terms/prostate-treatment-choice-localised/>, <https://onco.cc/terms/prostate-radiotherapy-fractionation/>, <https://onco.cc/terms/prostate-stampede-arms/>, <https://onco.cc/terms/prostate-adt-burden/>, <https://onco.cc/terms/prostate-crpc-sequencing/>, <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/terms/prostate-failed-programmes/>, <https://onco.cc/terms/prostate-uk-drug-approvals/>, <https://onco.cc/terms/prostate-focal-therapy/>, <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/overtreatment/>, <https://onco.cc/terms/number-needed-to-screen/>, <https://onco.cc/terms/other-cause-mortality/>, <https://onco.cc/terms/metastasis-free-survival/>, <https://onco.cc/terms/radiographic-progression-free-survival/>, <https://onco.cc/terms/chromoplexy/>, <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/>, <https://onco.cc/terms/polygenic-risk-score/>, <https://onco.cc/terms/neuroendocrine-differentiation/>, <https://onco.cc/terms/whole-mount-pathology/>, <https://onco.cc/terms/pi-rads/>, <https://onco.cc/terms/template-mapping-biopsy/>, <https://onco.cc/terms/bipolar-androgen-therapy/>, <https://onco.cc/terms/intermittent-androgen-deprivation/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/brca-reversion-mutations/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/biopsy/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/amplification/>, <https://onco.cc/terms/copy-number-variation-term/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/>, <https://onco.cc/terms/vus/>, <https://onco.cc/terms/somatic-mutations-wxs-wgs/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/nct06136624/>, <https://onco.cc/trials/nct06136650/>, <https://onco.cc/trials/nct06952803/>, <https://onco.cc/trials/nct06120491/>, <https://onco.cc/trials/nct06855277/>, <https://onco.cc/trials/nct06780670/>, <https://onco.cc/trials/nct07365995/>, <https://onco.cc/trials/nct06764485/>, <https://onco.cc/trials/mcrpc/>, <https://onco.cc/trials/himalayas-1/>, <https://onco.cc/trials/nct07311694/>, <https://onco.cc/trials/nct07615101/>, <https://onco.cc/trials/nct07649122/>, <https://onco.cc/trials/nct05381103/>, <https://onco.cc/trials/rtog-9601/>, <https://onco.cc/trials/horrad/>, <https://onco.cc/trials/pop-rt/>, <https://onco.cc/trials/nct06629779/>, <https://onco.cc/trials/nct05348577/>, <https://onco.cc/trials/nct05939414/>, <https://onco.cc/trials/nct06520345/>, <https://onco.cc/trials/nct07028853/>, <https://onco.cc/trials/nct01436968/>, <https://onco.cc/trials/nct03706365/>, <https://onco.cc/trials/nct04076059/>, <https://onco.cc/trials/nct05884398/>, <https://onco.cc/trials/nct07213674/>, <https://onco.cc/trials/nct04446117/>, <https://onco.cc/trials/nct06925737/>, <https://onco.cc/trials/nct07052214/>, <https://onco.cc/trials/nct05171816/>, <https://onco.cc/trials/nct07611110/>, <https://onco.cc/trials/nct04691804/>, <https://onco.cc/trials/nct05794906/>, <https://onco.cc/trials/nct02489318/>, <https://onco.cc/trials/nct04557059/>, <https://onco.cc/trials/nct03348670/>, <https://onco.cc/trials/nct06235151/>, <https://onco.cc/trials/nct02257736/>, <https://onco.cc/trials/nct06754085/>, <https://onco.cc/trials/nct06970847/>, <https://onco.cc/trials/nct04821622/>, <https://onco.cc/trials/nct05288166/>, <https://onco.cc/trials/nct07225946/>, <https://onco.cc/trials/nct04497844/>, <https://onco.cc/trials/nct03767244/>, <https://onco.cc/trials/nct02531516/>, <https://onco.cc/trials/nct01946204/>, <https://onco.cc/trials/nct06056830/>, <https://onco.cc/trials/nct03851640/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/protect/>, <https://onco.cc/trials/chaarted/>, <https://onco.cc/trials/latitude/>, <https://onco.cc/trials/vision/>, <https://onco.cc/trials/profound/>, <https://onco.cc/trials/propel/>, <https://onco.cc/trials/talapro-2/>, <https://onco.cc/trials/magnitude/>, <https://onco.cc/trials/embark/>, <https://onco.cc/trials/arasens/>, <https://onco.cc/trials/peace-1/>, <https://onco.cc/trials/enzamet/>, <https://onco.cc/trials/prosper/>, <https://onco.cc/trials/aramis/>, <https://onco.cc/trials/alsympca/>, <https://onco.cc/trials/psmaddition/>, <https://onco.cc/trials/capitello-281/>, <https://onco.cc/trials/goteborg-2/>, <https://onco.cc/trials/promis/>, <https://onco.cc/trials/transform-prostate/>, <https://onco.cc/trials/chhip/>, <https://onco.cc/trials/pace-b/> ;
  onco:people <https://onco.cc/people/chris-hoy/>, <https://onco.cc/people/jenny-donovan/>, <https://onco.cc/people/caroline-moore/>, <https://onco.cc/people/nicholas-van-as/>, <https://onco.cc/people/ros-eeles/>, <https://onco.cc/people/rakesh-heer/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995/>, <https://onco.cc/key-papers/paper-quigley-structural-variation-mcrpc-cell-2018/>, <https://onco.cc/key-papers/paper-prophecy-arv7-validation-jco-2019/>, <https://onco.cc/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/>, <https://onco.cc/key-papers/paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019/>, <https://onco.cc/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/>, <https://onco.cc/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/>, <https://onco.cc/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/>, <https://onco.cc/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/>, <https://onco.cc/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/>, <https://onco.cc/key-papers/paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020/>, <https://onco.cc/key-papers/paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-castro-germline-brca-prostate-outcomes-jco-2013/>, <https://onco.cc/key-papers/paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018/>, <https://onco.cc/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/>, <https://onco.cc/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/>, <https://onco.cc/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/>, <https://onco.cc/key-papers/paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011/>, <https://onco.cc/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/>, <https://onco.cc/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/>, <https://onco.cc/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/>, <https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/>, <https://onco.cc/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/>, <https://onco.cc/key-papers/paper-silver-psma-expression-normal-malignant-tissues-ccr-1997/>, <https://onco.cc/key-papers/paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014/>, <https://onco.cc/key-papers/paper-beltran-nepc-aurka-mycn-cancer-discov-2011/>, <https://onco.cc/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017/>, <https://onco.cc/key-papers/paper-labrecque-mcrpc-phenotypes-jci-2019/>, <https://onco.cc/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/>, <https://onco.cc/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/>, <https://onco.cc/key-papers/paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017/>, <https://onco.cc/key-papers/paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021/>, <https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/>, <https://onco.cc/key-papers/paper-propsma-hofman-lancet-2020/>, <https://onco.cc/key-papers/paper-therap-lancet-2021/>, <https://onco.cc/key-papers/paper-profound-nejm-2020/>, <https://onco.cc/key-papers/paper-vision-nejm-2021/>, <https://onco.cc/key-papers/paper-visakorpi-androgen-receptor-amplification-nat-genet-1995/>, <https://onco.cc/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/>, <https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/>, <https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/>, <https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/>, <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/>, <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/> ;
  onco:journals <https://onco.cc/journals/clinical-genitourinary-cancer/>, <https://onco.cc/journals/prostate-cancer-and-prostatic-diseases/>, <https://onco.cc/journals/urologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/opevesostat/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/aglatimagene-besadenovec/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/aaa817/>, <https://onco.cc/drugs/pf-07248144/>, <https://onco.cc/drugs/bnt324/>, <https://onco.cc/drugs/bms-986365/>, <https://onco.cc/drugs/jnj-87189401/>, <https://onco.cc/drugs/rinzimetostat/>, <https://onco.cc/drugs/hrs-4357/>, <https://onco.cc/drugs/fpi-2265/>, <https://onco.cc/drugs/xnw5004/>, <https://onco.cc/drugs/azd6621/>, <https://onco.cc/drugs/azd9750/>, <https://onco.cc/drugs/qlh12016/>, <https://onco.cc/drugs/amo959/>, <https://onco.cc/drugs/rv001v/>, <https://onco.cc/drugs/vudalimab/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/drugs/nuv-1511/>, <https://onco.cc/trials/alphabreak/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/trials/xalute/>, <https://onco.cc/drugs/pasritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/drugs/lu177-psma-it/>, <https://onco.cc/trials/eclipse-psma/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/>, <https://onco.cc/ideas/idea-alpha-first-mhspc/>, <https://onco.cc/targets/grpr/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/>, <https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/>, <https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/>, <https://onco.cc/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/>, <https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/>, <https://onco.cc/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/>, <https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/> ;
  onco:standardOfCare <https://onco.cc/terms/psa/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/trials/precision-mri/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/trials/erspc/>, <https://onco.cc/trials/plco-prostate/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/trials/embark/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/ideas/idea-psma-pet-guided-mdt/>, <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/trials/alphabreak/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/trials/xalute/>, <https://onco.cc/drugs/pasritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/trials/protect/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/cambridge-prognostic-group/>, <https://onco.cc/terms/percentage-gleason-pattern-4/>, <https://onco.cc/terms/cribriform-prostate-cancer/>, <https://onco.cc/technologies/mp-mri/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/chhip/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/adt/>, <https://onco.cc/terms/hot-flushes-on-hormone-therapy/>, <https://onco.cc/terms/treatment-induced-bone-loss/>, <https://onco.cc/terms/gynaecomastia/>, <https://onco.cc/drugs/relugolix/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/bicalutamide/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/terms/stress-urinary-incontinence/>, <https://onco.cc/terms/pelvic-floor-muscle-exercises/>, <https://onco.cc/terms/artificial-urinary-sphincter/>, <https://onco.cc/terms/erectile-dysfunction-after-prostate-cancer/>, <https://onco.cc/terms/priapism/>, <https://onco.cc/terms/acute-urinary-retention/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/psa-doubling-time/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/biochemical-recurrence/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/trials/embark/>, <https://onco.cc/terms/psa50/>, <https://onco.cc/terms/metastatic-spinal-cord-compression/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/trials/protect/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/embark/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/pain-management/>, <https://onco.cc/trials/protect/>, <https://onco.cc/trials/pivot/>, <https://onco.cc/trials/nct01310894/>, <https://onco.cc/terms/prostate-treatment-choice-localised/>, <https://onco.cc/terms/prostate-focal-therapy/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/trials/chhip/>, <https://onco.cc/trials/profit-trial/>, <https://onco.cc/trials/rtog-0415/>, <https://onco.cc/trials/pace-b/>, <https://onco.cc/trials/hypo-rt-pc/>, <https://onco.cc/trials/rtog-9408/>, <https://onco.cc/trials/eortc-22991/>, <https://onco.cc/terms/prostate-radiotherapy-fractionation/>, <https://onco.cc/terms/prostate-treatment-choice-localised/>, <https://onco.cc/trials/spcg-7/>, <https://onco.cc/trials/nct00002633/>, <https://onco.cc/trials/eortc-22863/>, <https://onco.cc/trials/eortc-22961/>, <https://onco.cc/trials/rtog-9202/>, <https://onco.cc/trials/dart-01-05-gicor/>, <https://onco.cc/trials/ascende-rt/>, <https://onco.cc/trials/rtog-0521/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/terms/prostate-adt-burden/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/radicals-rt/>, <https://onco.cc/trials/raves/>, <https://onco.cc/trials/getug-afu-17/>, <https://onco.cc/trials/artistic-meta-analysis/>, <https://onco.cc/trials/getug-afu-16/>, <https://onco.cc/trials/nct00567580/>, <https://onco.cc/trials/radicals-hd/>, <https://onco.cc/trials/rtog-9601/>, <https://onco.cc/trials/swog-8794/>, <https://onco.cc/trials/eortc-22911/>, <https://onco.cc/trials/chaarted/>, <https://onco.cc/trials/getug-afu-15/>, <https://onco.cc/trials/latitude/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/nct02489318/>, <https://onco.cc/trials/arches/>, <https://onco.cc/trials/enzamet/>, <https://onco.cc/trials/arasens/>, <https://onco.cc/trials/aranote/>, <https://onco.cc/trials/peace-1/>, <https://onco.cc/trials/patch-transdermal-oestradiol/>, <https://onco.cc/trials/swog-9346/>, <https://onco.cc/terms/prostate-stampede-arms/>, <https://onco.cc/terms/prostate-adt-burden/>, <https://onco.cc/trials/nct01946204/>, <https://onco.cc/trials/prosper/>, <https://onco.cc/trials/aramis/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/terms/prostate-uk-drug-approvals/>, <https://onco.cc/trials/cou-aa-301/>, <https://onco.cc/trials/cou-aa-302/>, <https://onco.cc/trials/affirm/>, <https://onco.cc/trials/prevail/>, <https://onco.cc/trials/tax-327/>, <https://onco.cc/trials/swog-9916/>, <https://onco.cc/trials/tropic/>, <https://onco.cc/trials/proselica/>, <https://onco.cc/trials/firstana/>, <https://onco.cc/trials/card/>, <https://onco.cc/trials/triton3/>, <https://onco.cc/trials/profound/>, <https://onco.cc/trials/vision/>, <https://onco.cc/trials/psmafore/>, <https://onco.cc/trials/therap/>, <https://onco.cc/trials/alsympca/>, <https://onco.cc/trials/peace-3/>, <https://onco.cc/terms/prostate-crpc-sequencing/>, <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/trials/imbassador250/>, <https://onco.cc/trials/keynote-921/>, <https://onco.cc/trials/keynote-641/>, <https://onco.cc/trials/keynote-991/>, <https://onco.cc/trials/ca184-043-ipilimumab/>, <https://onco.cc/trials/calgb-90401/>, <https://onco.cc/trials/comet-1/>, <https://onco.cc/trials/swog-s0421-atrasentan/>, <https://onco.cc/trials/enthuse-m1-zibotentan/>, <https://onco.cc/trials/ready-dasatinib/>, <https://onco.cc/trials/era-223/>, <https://onco.cc/trials/elm-pc-4-orteronel/>, <https://onco.cc/trials/tasquinimod-10tasq10/>, <https://onco.cc/terms/prostate-failed-programmes/> .